REYON Pharmaceutical (A102460) Stock Overview
Manufactures and sells medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A102460 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
REYON Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,020.00 |
| 52 Week High | ₩13,200.00 |
| 52 Week Low | ₩9,100.00 |
| Beta | 0.47 |
| 1 Month Change | -9.57% |
| 3 Month Change | -12.64% |
| 1 Year Change | -7.73% |
| 3 Year Change | -36.50% |
| 5 Year Change | -82.78% |
| Change since IPO | -5.43% |
Recent News & Updates
Is REYON Pharmaceutical (KRX:102460) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...REYON Pharmaceutical's (KRX:102460) Profits May Not Reveal Underlying Issues
REYON Pharmaceutical Co., Ltd.'s ( KRX:102460 ) healthy profit numbers didn't contain any surprises for investors. We...Recent updates
Shareholder Returns
| A102460 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.7% | -1.5% | 9.4% |
| 1Y | -7.7% | -3.5% | 109.6% |
Return vs Industry: A102460 underperformed the KR Pharmaceuticals industry which returned -3.5% over the past year.
Return vs Market: A102460 underperformed the KR Market which returned 109.6% over the past year.
Price Volatility
| A102460 volatility | |
|---|---|
| A102460 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in KR Market | 17.6% |
| 10% least volatile stocks in KR Market | 5.1% |
Stable Share Price: A102460 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A102460's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1955 | 440 | Soon-Ock Jung | reyonpharm.co.kr |
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study.
REYON Pharmaceutical Co., Ltd. Fundamentals Summary
| A102460 fundamental statistics | |
|---|---|
| Market cap | ₩183.78b |
| Earnings (TTM) | -₩40.59b |
| Revenue (TTM) | ₩145.22b |
Is A102460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A102460 income statement (TTM) | |
|---|---|
| Revenue | ₩145.22b |
| Cost of Revenue | ₩111.98b |
| Gross Profit | ₩33.24b |
| Other Expenses | ₩73.83b |
| Earnings | -₩40.59b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21k |
| Gross Margin | 22.89% |
| Net Profit Margin | -27.95% |
| Debt/Equity Ratio | 104.0% |
How did A102460 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/18 19:13 |
| End of Day Share Price | 2026/08/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
REYON Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| JooYong Kim | Bookook Securities Co. Ltd |